GEN - Genetic Engineering & Biotech NewsOriginal article
Palomar Labs Spins Out Ariadne Bio to Advance Non-Hallucinogenic Therapy for Parkinson’s Apathy
AB-300Positive
AI Analysis
Summary
Palomar Labs spun out Ariadne Bio to develop AB-300, a non-hallucinogenic serotonin 2A receptor agonist for treating Parkinson's-related apathy, supported by preclinical data and funding from The Michael J. Fox Foundation.
Importance:4/10
Sentiment:
0.60
spinoutParkinson's diseaseneurologyserotonin receptor agonistpreclinical
Related Companies
Read the original article
Published by GEN - Genetic Engineering & Biotech News on September 18, 2026 3:11 PM